Phase I prospective trial of TAS-102 (trifluride and tipiracil) and radioembolization with 90Y resin microspheres for chemo-refractory colorectal liver metastases.

Nicholas Fidelman,Chloe E. Atreya,Madeline J Griffith,Marion Alexandra Milloy,Julia Carnevale,Pelin Cinar,Alan P. Venook,Katherine Van Loon

Phase I prospective trial of TAS-102 (trifluride and tipiracil) and radioembolization with 90Y resin microspheres for chemo-refractory colorectal liver metastases.

2020

Nicholas Fidelman
Chloe E. Atreya
Madeline J Griffith
Marion Alexandra Milloy
Julia Carnevale
Pelin Cinar
Alan P. Venook
Katherine Van Loon

110Background: Clinical efficacy of Yttrium-90 (90Y) radioembolization (TARE) for patients with chemotherapy-refractory metastatic colorectal cancer (mCRC) is limited by extrahepatic disease progre...

Keywords:

Gastroenterology
Internal medicine
Tipiracil
Medicine
Pathology
Microsphere
Refractory
Oncology
prospective trial
Colorectal cancer
Tare weight
clinical efficacy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations